Y-mAbs Shares Fall After Outlook, 4Q Revenue Miss

Dow Jones

Mar 04, 2025

By Katherine Hamilton

Y-mAbs Therapeutics shares fell after it missed expectations with its revenue for the fourth quarter and estimate for 2025.

The stock declined 10% to $4.66 in pre-market trading Tuesday. Shares have lost half their value over the past three months.

The cancer treatment biopharmaceutical company posted a loss of $6.8 million, or 15 cents a share, for the three months ended Dec. 31, compared with $988 million, or 2 cents a share, the prior year.

Revenue increased 5% to $26.5 million, behind analysts' expectations of $26.7 million, according to FactSet.

Y-mAbs expects total revenue in 2025 to be $75 million to $90 million, while analysts polled by FactSet are anticipating $103.6 million.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 04, 2025 08:08 ET (13:08 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2516676920"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516676920\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2516676920?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-04 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516676920","market":"other","top_or_hot":-1,"title":"Y-mAbs Shares Fall After Outlook, 4Q Revenue Miss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares fell after it missed expectations with its revenue for the fourth quarter and estimate for 2025. \n</p>\n<p>\n  The stock declined 10% to $4.66 in pre-market trading Tuesday. Shares have lost half their value over the past three months. \n</p>\n<p>\n  The cancer treatment biopharmaceutical company posted a loss of $6.8 million, or 15 cents a share, for the three months ended Dec. 31, compared with $988 million, or 2 cents a share, the prior year. \n</p>\n<p>\n  Revenue increased 5% to $26.5 million, behind analysts' expectations of $26.7 million, according to FactSet. \n</p>\n<p>\n  Y-mAbs expects total revenue in 2025 to be $75 million to $90 million, while analysts polled by FactSet are anticipating $103.6 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 04, 2025 08:08 ET (13:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Y-mAbs Shares Fall After Outlook, 4Q Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nY-mAbs Shares Fall After Outlook, 4Q Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-04 21:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares fell after it missed expectations with its revenue for the fourth quarter and estimate for 2025. \n</p>\n<p>\n  The stock declined 10% to $4.66 in pre-market trading Tuesday. Shares have lost half their value over the past three months. \n</p>\n<p>\n  The cancer treatment biopharmaceutical company posted a loss of $6.8 million, or 15 cents a share, for the three months ended Dec. 31, compared with $988 million, or 2 cents a share, the prior year. \n</p>\n<p>\n  Revenue increased 5% to $26.5 million, behind analysts' expectations of $26.7 million, according to FactSet. \n</p>\n<p>\n  Y-mAbs expects total revenue in 2025 to be $75 million to $90 million, while analysts polled by FactSet are anticipating $103.6 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 04, 2025 08:08 ET (13:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YMAB","symbol_name":"Y-mAbs Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2516676920","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516676920","pubTimestamp":1741093680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Y-mAbs Therapeutics shares fell after it missed expectations with its revenue for the fourth quarter and estimate for 2025.The stock declined 10% to $4.66 in pre-market trading Tuesday. Shares have lost half their value over the past three months.The cancer treatment biopharmaceutical company posted a loss of $6.8 million, or 15 cents a share, for the three months ended Dec. 31, compared with $988 million, or 2 cents a share, the prior year.Revenue increased 5% to $26.5 million, behind analysts' expectations of $26.7 million, according to FactSet.Y-mAbs expects total revenue in 2025 to be $75 million to $90 million, while analysts polled by FactSet are anticipating $103.6 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"YMAB":"Y-mAbs Therapeutics, Inc."},"translate_title":"Y-mAbs股价因展望、第四季度营收未达预期而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YMAB":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Y-mAbs Therapeutics shares fell after it missed expectations with its revenue for the fourth quarter and estimate for 2025. \n\n\n  The stock declined 10% to $4.66 in pre-market trading Tuesday. Shares have lost half their value over the past three months. \n\n\n  The cancer treatment biopharmaceutical company posted a loss of $6.8 million, or 15 cents a share, for the three months ended Dec. 31, compared with $988 million, or 2 cents a share, the prior year. \n\n\n  Revenue increased 5% to $26.5 million, behind analysts' expectations of $26.7 million, according to FactSet. \n\n\n  Y-mAbs expects total revenue in 2025 to be $75 million to $90 million, while analysts polled by FactSet are anticipating $103.6 million. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2025 08:08 ET (13:08 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}